Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
393.5 USD | +0.10% | -1.69% | -3.30% |
Apr. 18 | Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain | MT |
Apr. 17 | UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.30% | 102B | |
+1.79% | 96.07B | |
-0.79% | 21.66B | |
-18.35% | 20.77B | |
-7.66% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B | |
-21.69% | 8.57B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Barclays Adjusts Price Target on Vertex Pharmaceuticals to $307 From $291, Reiterates Overweight Rating